Skip to main content
TipRanks
Go Ultimate75% OFF

Cowealth Medical Holding Co., Ltd. (4745) AI Stock Analysis

TW:4745

Cowealth Medical Holding Co., Ltd.

(TPEx:4745)

Select Model
Rating:40Underperform
Price Target:TWD 10.00â–¼(-2.91% Downside)
Action:initiatedcoverage
Date:11/09/26

Weak financial performance from declining revenues and losses is the primary driver of the low score, compounded by poor valuation metrics and bearish technical signals.

Positive Factors
Manageable LeverageA debt-to-equity ratio around 0.35 indicates a comparatively moderate and stable capital structure for the business. This preserves financial flexibility to support operations and future investment, while reducing the balance-sheet strain that can amplify downturns.
Negative Factors
Revenue and Profitability DeclineThe 2025 decline in revenue alongside a swing to operating and net losses shows that recent earnings power has weakened materially. Continued pressure on demand, price mix, or cost leverage could reduce reinvestment capacity and make a return to sustainable profitability more difficult.

Cowealth Medical Holding Co., Ltd. (4745) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%60%TW:4745-43.72%SPY+14.30%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 698.63M
Dividend Yield
―
Average Volume (3M)
24.97K
Price to Earnings (P/E)
-3.2
Beta (1Y)
0.31
Revenue Growth
-13.59%
EPS Growth
-221.93%
Country
TW
Employees
919
Sector
General
Sector Strength
55
Industry
Medical - Distribution

Cowealth Medical Holding Co., Ltd. Business Overview & Revenue Model

Company Description

Cowealth Medical Holding Co., Ltd., together with its subsidiaries, engages in trading of medical equipment, reagents, and spare parts in Taiwan, China, and Hong Kong. It operates in two segments, Sells Equipment, and Sells Reagents and Others. The c...

Cowealth Medical Holding Co., Ltd. Financial Statement Overview

Summary

Sharp revenue decline, compressed margins, and shift to net losses in the income statement, combined with volatile cash flows, result in weak financial performance despite balance sheet stability.

Income Statement

25Negative

Balance Sheet

68Positive

Cash Flow

38Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Jun 2024Dec 2022Dec 2021
Income Statement
Total Revenue2.90B2.96B4.19B4.81B5.63B5.14B
Gross Profit386.14M353.22M791.52M996.45M1.10B1.06B
EBITDA-256.46M-225.35M168.15M359.59M470.59M429.04M
Net Income-294.84M-246.56M629.00K55.71M94.11M139.46M
Balance Sheet
Total Assets7.19B7.04B6.96B6.64B7.21B5.40B
Cash, Cash Equivalents and Short-Term Investments636.46M1.14B1.23B927.28M1.43B842.68M
Total Debt601.44M1.01B872.70M647.24M956.20M913.34M
Total Liabilities2.27B1.99B1.76B1.61B2.00B1.88B
Stockholders Equity2.70B2.87B2.80B2.72B2.84B2.57B
Cash Flow
Free Cash Flow-543.21M836.00K316.52M-191.47M-293.96M-155.04M
Operating Cash Flow-532.04M15.53M373.97M45.02M-267.59M-118.38M
Investing Cash Flow76.13M-174.03M40.60M-173.28M-271.00M-13.51M
Financing Cash Flow-142.12M-122.23M-238.92M-316.48M1.07B-198.56M

Cowealth Medical Holding Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:4745 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:4745TW:474540UnderperformTWD 685.38M-3.19――-13.59%-221.93%

* General Sector Average

Performance Comparison

-50%-25%0%25%TW:4745TW:4117TW:6817TW:6999TW:7726TW:7835Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:4745 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:4745Cowealth Medical Holding Co., Ltd.10.30-8.45-45.07%
TW:4117General Biologicals Corp.7.41-4.79-39.26%
TW:6817Winston Medical Supply Co., Ltd.37.50-60.57-61.76%
TW:6999Han Biomedical, Inc.24.45-6.02-19.75%
TW:7726CARILEX MEDICAL INC.32.15-5.10-13.69%
TW:7835H2U Corporation14.55-25.40-63.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026